文献速递胸部肿瘤放疗放疗物理与技术

质子与光子放疗对肺癌健康相关生活质量的影响评估

Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-04-06

本研究纳入经模型筛选考虑质子治疗的肺癌患者,比较调强质子治疗(IMPT)与光子调强放疗(IMRT)对健康相关生活质量(HRQoL)的影响。共171例IMPT和71例IMRT患者,中位随访8个月,采用EQ-5D-5L、EQ-VAS和EORTC QLQ-C30 GHS评估。结果表明IMPT与IMRT在HRQoL上无统计学显著差异,也未达临床相关差异。

要点

  • IMPT与IMRT在EQ-5D-5L、EQ-VAS和GHS的系数估计分别为-0.022、-0.008和-0.014。
  • 差异均无统计学显著性,也未超过最小重要差异阈值(0.03和0.05)。
  • 基线HRQoL两组相似,随访中未见IMPT带来额外HRQoL获益。

核心结论

  • IMPT与IMRT在肺癌患者HRQoL上无显著差异,也未达临床相关差异。

研究设计与样本

  • 纳入经模型筛选考虑IMPT并接受IMPT或IMRT治疗的肺癌患者,共171例IMPT和71例IMRT,平均随访8个月。
  • 采用EQ-5D-5L、EQ-VAS和EORTC QLQ-C30 GHS在基线、3、6、12个月及每年至5年评估HRQoL。
  • 使用广义线性混合效应模型分析放疗方式对HRQoL的影响,并以多重插补和倾向评分加权平衡组间。

主要发现

  • 疾病以III期非小细胞肺癌为主,多数患者接受化疗,两组基线平均HRQoL评分相似。
  • IMPT对比IMRT的系数估计为EQ-5D-5L -0.022、EQ-VAS -0.008、GHS -0.014。
  • 上述差异均无统计学显著性,也未达临床相关差异。

关键数值与推荐

  • 最小重要差异阈值:EQ-5D-5L为0.03,EQ-VAS和GHS为0.05。
  • 最终模型固定效应包括放疗方式、WHO体能状态、基线HRQoL和基线呼吸困难。

临床怎么用

  • 对于经模型筛选适合IMPT的肺癌患者,IMPT未显示HRQoL优势,决策时应综合考量其他临床获益。
  • HRQoL随访应结合基线HRQoL和呼吸困难等因素进行解读。

局限性

  • 平均随访仅8个月,长期HRQoL影响未充分评估。
  • IMPT组与IMRT组样本量不平衡(171 vs 71),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A more conformal dose deposition of intensity-modulated proton therapy (IMPT) may enhance health-related quality of life (HRQoL) through reduced radiation-induced toxicities, versus photon-based intensity-modulated radiotherapy (IMRT). However, most patients are selected for IMPT based on relative reduction in mean heart dose and correlated 2-year mortality. A HRQoL difference would thus not necessarily be expected. This study evaluates HRQoL outcomes in patients with lung cancer treated with IMPT versus IMRT. MATERIALS AND METHODS: Patients considered for IMPT via the model-based approach and treated with IMPT or IMRT were included. HRQoL was measured using EQ-5D-5 L, EQ-VAS, and EORTC QLQ-C30 Global Health Status (GHS) at baseline, 3, 6, 12 months, and annually up to 5 years. Generalised linear mixed effects (GLM) models were developed in R to assess the impact of radiation modality on HRQoL. Missing data were handled using multiple imputation with propensity score weighting to balance treatment groups. Radiation modality, WHO performance status, baseline HRQoL, and baseline dyspnoea were included as fixed effects in final models. Minimal important difference cut-offs were 0.03 (EQ-5D-5 L), and 0.05 (EQ-VAS; GHS). RESULTS: 171 IMPT and 71 IMRT patients were included (mean follow-up: 8 months). Disease was predominantly stage III non-small cell lung cancer and most patients received chemotherapy. Baseline mean HRQoL scores were similar between groups. Coefficient estimates for IMPT versus IMRT were -0.022 (EQ-5D-5 L), -0.008 (EQ-VAS) and -0.014 (GHS). Differences were not deemed statistically significant nor clinically relevant. CONCLUSION: Certain clinical advantages for IMPT have previously been demonstrated, but no significant difference in HRQoL between IMPT and IMRT was observed.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sugden BM, Witlox WJA, Cortiula F, et al. Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer. Clin Transl Radiat Oncol. 2026. PMID: 42028345. doi:10.1016/j.ctro.2026.101160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。